netbook
desktop
mobile
tablet-landscape
tablet
phone-landscape
phone
Research to Prevent Blindness

Reversing Retinal Degenerative Diseases: We’re One Step Closer

Degenerative disorders affecting the retinal pigment epithelium (RPE), such as age-related macular degeneration and autosomal recessive bestrophinopathy, can ultimately lead to blindness. Some of these life-changing disorders are the result of mutations in a single gene, called BEST1.

Although the genetic defect in BEST1 was identified almost two decades ago, its physiological role—how it does what it does, was unclear. Now, researchers from Columbia University and University of Rochester have used a novel approach to solve this mystery. Today, they published their pioneering study in the journal eLife

RPB Physician-Scientist Awardee Stephen H. Tsang, MD, PhD, of Columbia University, at work in his lab.

The researchers created a “disease-in-a-dish,” meaning that they coaxed skin cells taken from an adult patient first back into an embryonic-like state (called induced pluripotent stem cells, or iPSCs) and then into RPE cells to create a model of retinal degenerative disease. Then they assessed physiological properties of the RPE cells carrying normal or mutated BEST1 via innovative, interdisciplinary approaches to pinpoint the exact role of the BEST1 gene.

The researchers were also able to show that RPE cells that carry the BEST1 gene mutations, which are the same cells that are damaged by degenerative diseases, can have their damage reversed by providing healthy copies of the BEST1 gene (through viral gene supplementation, which uses a specially selected virus to “carry” new genes into the cells).

“Our team provided evidence that autosomal recessive bestrophinopathy is a ‘chloride channelopathy’ and is a treatable disorder,” said RPB Physician-Scientist Awardee Stephen H. Tsang, MD, PhD, Associate Professor of Ophthalmology and Associate Professor of Pathology and Cell Biology at Columbia University, and Tingting Yang, PhD, Assistant Professor of Pharmacology and Physiology at University of Rochester.

 

 

Related News: Feature Story, Gene Therapy, Macular Degeneration, Retina Disorders , Stem Cell Therapy, Top Story

Dr. Palczewski and lab members

An RPB Awardee Tackles Inherited Retinal Diseases

Dr. Krzysztof Palczewski develops and applies cutting-edge gene editing techniques to challenging genetic conditions.

Read More

 
Dr. David Calkins

RPB and Association of University Professors of Ophthalmology Announce 2023 Recipient of RPB David F. Weeks Award for Outstanding Vision Research

David J. Calkins, PhD, is recognized for ground-breaking contributions to the field of vision research.

Read More

 
RPB logo

Research to Prevent Blindness and the American Academy of Ophthalmology Award New Research Grants to Improve Eye Care

Award recipients to use the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight) clinical database to improve care for all patients.

Read More

 
RPB logo

Grant from Research to Prevent Blindness and Castle Biosciences Supports Medical Student Research in Ocular Cancer

Research to Prevent Blindness and Castle Biosciences are partnering to provide new opportunities for medical students to pursue ocular cancer research.

Read More

 
RPB logo

New Glaucoma Research Grant Available

Research to Prevent Blindness and Aerie Pharmaceuticals are partnering to provide grant opportunities to support novel research in glaucoma.

Read More

 
RPB logo

New Vision Science Research Grant for Students of Osteopathic Medicine

RPB and the AOCOO-HNS Foundation are launching a multi-year partnership to provide funding to increase research opportunities in vision science for students of osteopathic medicine.

Read More

 

Subscribe

Get our email updates filled with the latest news from our researchers about preventing vision loss, treating eye disease and even restoring sight. Unsubscribe at any time. Under our privacy policy, we'll never share your contact information with a third party.